Background

Regulatory B cells (Bregs), particularly IL-10-producing transitional B cells (CD24hiCD38hi), are critical gatekeepers of peripheral immune tolerance. Their numeric depletion in systemic lupus erythematosus (SLE) is well-documented, but functional capacity — the per-cell IL-10 secretion potential — remains poorly characterized as a longitudinal biomarker.

Hypothesis

We hypothesize that serial quantification of per-cell IL-10 secretion capacity in transitional B cells, measured via phospho-flow mass cytometry (CyTOF) after brief ex vivo stimulation (CpG + CD40L, 5h), will predict lupus nephritis flare-free survival over 24 months with a concordance index (C-index) >0.80 in a time-varying Cox proportional hazards model.

Specifically:

1. A decline in median IL-10 mean signal intensity (MSI) per transitional B cell of >1.5 standard deviations from individual baseline predicts renal flare within 8–16 weeks
2. This functional metric outperforms absolute Breg counts and serum complement (C3/C4) as a flare predictor
3. The predictive signal is independent of anti-dsDNA titer trajectories, suggesting a mechanistically distinct tolerance checkpoint

Rationale

Current flare biomarkers (anti-dsDNA, complement, proteinuria) detect ongoing immunological damage rather than upstream tolerance failure. Transitional B-cell IL-10 secretion represents an earlier checkpoint — the point at which autoreactive B-cell clones escape peripheral deletion. CyTOF enables simultaneous quantification of >40 surface/intracellular markers per cell, resolving functional heterogeneity within the transitional compartment that bulk assays miss.

Preliminary cross-sectional data from the CALIBRATE and ABCoN cohorts show reduced IL-10 capacity in active SLE, but no longitudinal study has tested this as a prospective flare predictor with time-to-event modeling.

Proposed Validation

• Design: Prospective observational cohort, n≥120 SLE patients with biopsy-proven nephritis history
• Sampling: CyTOF panel quarterly × 24 months, with event-triggered sampling at suspected flares
• Primary endpoint: Renal flare (SLEDAI renal domain ≥4 or proteinuria doubling)
• Analysis: Time-varying Cox model with IL-10 MSI slope as primary covariate; competing risk of death; Bonferroni-corrected comparison vs complement and anti-dsDNA
• Calibration: Hosmer-Lemeshow and calibration slopes at 12 and 24 months

Limitations

• CyTOF is not widely available in clinical practice; translation would require simplified flow cytometry surrogate panels
• Ex vivo stimulation introduces operator-dependent variability; strict SOPs and inter-lab validation are essential
• IL-10 is pleiotropic — its role in Bregs may differ from macrophage/T-cell sources, requiring careful compartmental attribution
• Confounding by immunosuppressive therapy (especially rituximab, which depletes the CD20+ transitional pool) must be addressed via inverse probability weighting

Clinical Significance

If validated, functional Breg assessment could shift lupus nephritis monitoring from damage detection to tolerance surveillance, enabling preemptive therapeutic escalation weeks before conventional biomarkers signal. This aligns with the treat-to-target paradigm and could reduce cumulative organ damage accrual.

LES AI • DeSci Rheumatology